Phospho-NEK9 (T210) Antibody

What is NEK9 and why is phosphorylation at T210 significant?

NEK9 (Never in mitosis A-related kinase 9) is a serine/threonine protein kinase that functions as a pleiotropic regulator of mitotic progression, participating in the control of spindle dynamics and chromosome separation. The phosphorylation at Threonine 210 (T210) represents a critical regulatory modification that modulates NEK9's kinase activity .

This specific phosphorylation site becomes particularly significant because:

• When NEK9 is complexed with the FACT (facilitates chromosome transcription) complex, it exhibits markedly elevated phosphorylation at T210

• During mitosis, NEK9 is not phosphorylated at T210

• NEK9 can be phosphorylated by CDK1 in vitro at this position

• T210 phosphorylation status affects NEK9's interaction with protein partners and its role in cell cycle regulation

What are the main applications for Phospho-NEK9 (T210) antibodies in research?

Phospho-NEK9 (T210) antibodies can be applied in multiple experimental contexts:

These applications allow researchers to detect endogenous levels of NEK9 protein specifically when phosphorylated at T210, enabling studies of its regulation and function in various cellular contexts .

What species reactivity can be expected with commercially available Phospho-NEK9 (T210) antibodies?

Most commercially available Phospho-NEK9 (T210) antibodies exhibit reactivity across multiple mammalian species:

• Human: Confirmed reactivity in multiple cell lines (HepG2, HeLa)

• Mouse: Demonstrated reactivity in several research reports

• Rat: Reactivity reported but sometimes with variable efficiency

This cross-species reactivity is attributed to the high conservation of the amino acid sequence surrounding the T210 phosphorylation site across these species. The immunogens used to generate these antibodies typically derive from human NEK9 sequences around the T210 phosphorylation site (amino acids 176-225), but the sequence homology allows detection in multiple species .

How should researchers optimize Western blot protocols for Phospho-NEK9 (T210) antibody detection?

For optimal Western blot results with Phospho-NEK9 (T210) antibodies, implement the following methodological considerations:

• Sample preparation:

  • Immediately add phosphatase inhibitors to all lysate buffers

  • Maintain cold temperatures throughout protein extraction

  • Consider using phosphate-enrichment approaches for low-abundance samples

• Gel electrophoresis and transfer:

  • Use 8% SDS-PAGE gels to properly resolve the ~107-130 kDa protein

  • Transfer at lower voltage for longer duration to ensure complete transfer of higher molecular weight proteins

• Antibody incubation:

  • Block with 5% BSA (not milk) in TBST to prevent phosphatase activity

  • Start with 1:1000 dilution in primary antibody incubation and optimize as needed

  • Include positive control lysates (e.g., HepG2 cell extracts)

  • Consider overnight incubation at 4°C for enhanced sensitivity

• Validation controls:

  • Include peptide competition assays with the immunizing phosphopeptide to confirm specificity

  • Consider dephosphorylation controls (λ-phosphatase treated samples)

  • Compare with total NEK9 antibody staining to assess phosphorylation levels relative to total protein

Western blot analysis typically shows a band at approximately 130 kDa, slightly higher than the predicted 107 kDa, likely due to post-translational modifications .

What are the recommended methods for preserving phosphorylation status during immunohistochemistry procedures?

Preserving phosphorylation signals during IHC requires specific technical considerations:

• Tissue collection and fixation:

  • Process tissues rapidly after collection to minimize phosphatase activity

  • Use phosphatase inhibitors in all solutions during tissue handling

  • Prefer shorter formaldehyde fixation times (4-8 hours) to prevent epitope masking

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval using EDTA pH 9.0 buffer typically yields better results than citrate buffer for phospho-epitopes

  • Carefully optimize retrieval time and temperature for each tissue type

• Signal amplification:

  • Consider using amplification systems such as polymer-HRP or tyramide signal amplification for low-abundance phospho-epitopes

  • Automated staining systems can provide more consistent results for phospho-epitopes

• Controls:

  • Include phosphatase-treated sections as negative controls

  • Use tissues with known high expression (e.g., certain cancer types) as positive controls

Research has demonstrated that NEK9 phosphorylated at T210 can be detected in human colon tissues, with staining localized to both cytoplasm and nucleus. NEK9 expression has been documented in various lung cancer types, including adenocarcinomas (57.9%), squamous cell carcinomas (96.4%), large cell neuroendocrine carcinomas (100%), and small cell carcinomas (100%) .

What experimental approaches can distinguish between T210 phosphorylation-dependent and independent functions of NEK9?

To experimentally distinguish between phosphorylation-dependent and independent functions of NEK9, researchers should consider these methodological approaches:

• Mutational analysis:

  • Generate expression constructs containing NEK9 T210A (phospho-deficient) or T210D/E (phospho-mimetic) mutations

  • Perform rescue experiments in NEK9-knockdown backgrounds to assess functional complementation

  • Monitor specific cellular processes (cell cycle progression, mitotic phenotypes) to identify differential effects

• Temporal dynamics assessment:

  • Synchronize cells at different cell cycle stages and assess T210 phosphorylation status

  • Correlate phosphorylation patterns with specific cellular functions during cell cycle progression

  • Use inhibitors of upstream kinases (e.g., CDK1) to manipulate phosphorylation status

• Phosphorylation-dependent protein interactions:

  • Perform co-immunoprecipitation experiments using wildtype vs. T210A/D mutants

  • Identify differential binding partners using mass spectrometry

  • Validate functionally significant interactions using targeted approaches

Research has shown that expression of NEK9 T210A can restore proliferation in p53 mutant cells, suggesting that some NEK9 functions in G1/S progression may be kinase-activity independent or rely on alternative regulatory mechanisms beyond T210 phosphorylation .

How does NEK9 T210 phosphorylation status change during cell cycle progression and what are the regulatory mechanisms?

The phosphorylation status of NEK9 at T210 exhibits dynamic regulation throughout the cell cycle with distinct patterns that correlate with specific cellular functions:

• Cell cycle-dependent regulation:

  • T210 phosphorylation is elevated during interphase, particularly when NEK9 is complexed with the FACT complex

  • During mitosis, NEK9 is not phosphorylated at T210, indicating a shift in its activation mechanism

  • These changes align with NEK9's differential roles in G1/S transition versus mitotic progression

• Regulatory mechanisms:

  • CDK1 can phosphorylate NEK9 at T210 in vitro, suggesting cell cycle-dependent regulation

  • Autophosphorylation may contribute to T210 phosphorylation status

  • The FACT complex association markedly increases T210 phosphorylation

  • DNA damage prevents phosphorylation, indicating integration with cellular stress response pathways

• Functional implications:

  • T210 phosphorylation and kinase activity are primarily detectable during G2/M phase and required for G2 phase progression

  • G1/S transition functions may utilize different regulatory mechanisms or phosphorylation sites

  • The switch between phosphorylated and non-phosphorylated states may facilitate transitions between NEK9's diverse cellular functions

These dynamics suggest a complex regulatory network controlling NEK9 function throughout the cell cycle, with T210 phosphorylation serving as a critical regulatory node in this network .

What is the relationship between NEK9 T210 phosphorylation, p53 status, and cancer cell proliferation?

Research has revealed a complex relationship between NEK9 phosphorylation, p53 functionality, and cancer cell proliferation:

These findings indicate that while T210 phosphorylation is important for some NEK9 functions, its role in supporting cancer cell proliferation in p53-deficient contexts may involve additional or alternative regulatory mechanisms .

How do NEK9 T210 phosphorylation patterns compare with other mitotic kinase phosphorylation sites, such as PLK1 T210?

The T210 phosphorylation sites on NEK9 and PLK1 represent intriguing parallels in mitotic regulation, despite occurring in distinct kinases:

• Structural and functional comparisons:

  • Both NEK9 and PLK1 are serine/threonine kinases involved in mitotic regulation

  • Both contain a T210 phosphorylation site that regulates kinase activity

  • PLK1 T210 phosphorylation elevates kinase activity and affects mitotic progression

  • NEK9 T210 phosphorylation similarly regulates its activity, but with different temporal dynamics

• Differential regulation:

  • PLK1 is phosphorylated at T210 during mitosis

  • NEK9 is not phosphorylated at T210 during mitosis, but rather during interphase

  • DNA damage prevents phosphorylation at both sites, suggesting integration with stress response pathways

  • This indicates potentially complementary roles in cell cycle regulation

• Methodological considerations:

  • Antibodies against each phosphorylation site must be carefully validated for specificity

  • Cell synchronization approaches are critical for accurate temporal profiling

  • Combined analysis of both kinases may provide more comprehensive understanding of mitotic regulatory networks

This comparative analysis suggests that while structurally similar, these phosphorylation events likely serve distinct regulatory functions in orchestrating different aspects of cell cycle progression .

How can cell-based ELISA approaches enhance quantitative analysis of NEK9 T210 phosphorylation?

Cell-based ELISA techniques offer several advantages for studying NEK9 T210 phosphorylation in intact cellular contexts:

• Methodological advantages over traditional Western blotting:

  • Higher throughput capability for screening multiple conditions

  • More quantitative and reproducible measurements

  • Preservation of cellular architecture and spatial information

  • Conservation of cell culture and treatment reagents

  • Faster results with data readily available for analysis

• Optimized protocol considerations:

  • Cells should be fixed in 96-well plates under defined conditions

  • Dual antibody approach can normalize phospho-signal to total NEK9 levels

  • Crystal violet staining allows normalization to cell number

  • Careful optimization of antibody concentrations is critical for signal-to-noise ratio

• Applications in NEK9 research:

  • Screening cellular conditions that affect T210 phosphorylation status

  • Temporal profiling of phosphorylation dynamics during cell cycle

  • Evaluating effects of potential therapeutic compounds

  • Quantifying phosphorylation responses to cellular stressors

These approaches enable more systematic and quantitative evaluation of the factors regulating NEK9 T210 phosphorylation in physiologically relevant cellular contexts .

What are the implications of NEK9 T210 phosphorylation for understanding therapeutic vulnerabilities in p53-mutant cancers?

The relationship between NEK9 phosphorylation and p53-mutant cancer cell dependency suggests potential therapeutic opportunities:

• Therapeutic targeting rationale:

  • p53 mutations occur in approximately 50% of human cancers

  • NEK9 dependency in p53-mutant contexts suggests a potential synthetic lethal relationship

  • NEK9 inhibition could selectively target p53-deficient cancer cells while sparing normal cells

• Biomarker development considerations:

  • Phospho-NEK9 (T210) status might serve as a biomarker for patient stratification

  • Combined assessment of NEK9 expression and p53 mutation status may predict patient outcomes

  • Kaplan-Meier analysis shows NEK9/p53 double-positive cases have significantly poorer prognosis

• Future research directions:

  • Development of small molecule inhibitors targeting NEK9

  • Investigation of downstream effectors as alternative therapeutic targets

  • Evaluation of combination approaches with existing therapeutic modalities

  • Further characterization of the NEK9-T210 phosphorylation-independent mechanisms supporting cancer cell proliferation

These findings suggest that NEK9 may represent a promising therapeutic target for p53-mutant cancers, but further research is needed to fully understand the relationship between its phosphorylation status and potential intervention points .

What current gaps exist in our understanding of the NEK9-FACT complex interaction and how might phospho-specific antibodies help address these?

Several knowledge gaps remain regarding the NEK9-FACT complex interaction and its regulation by T210 phosphorylation:

Addressing these questions could significantly advance our understanding of how NEK9 phosphorylation status impacts its role in transcriptional regulation and cell cycle progression, potentially revealing new therapeutic opportunities .

How can researchers integrate phosphorylation data with other NEK9 regulatory mechanisms to build comprehensive pathway models?

Building integrative models of NEK9 regulation requires synthesizing phosphorylation data with other regulatory mechanisms:

• Multidimensional data integration approach:

  • Phosphorylation profiling of multiple NEK9 sites beyond T210

  • Protein interaction network mapping under various cellular conditions

  • Transcriptomic and proteomic profiling in NEK9 wildtype versus mutant backgrounds

  • Structural biology approaches to understand how phosphorylation affects protein conformation

• Computational modeling considerations:

  • Use of systems biology approaches to model NEK9 in the broader kinase network

  • Integration of temporal dynamics data across cell cycle phases

  • Machine learning algorithms to identify patterns in complex datasets

  • Pathway enrichment analysis to connect NEK9 to broader cellular processes

• Experimental validation strategies:

  • CRISPR-Cas9 genome editing to introduce specific phosphorylation site mutations

  • Optogenetic approaches to manipulate NEK9 activity with temporal precision

  • Single-cell analyses to capture heterogeneity in NEK9 regulation

  • In vivo models to validate predictions in physiological contexts

This integrated approach would significantly advance our understanding of how NEK9 phosphorylation connects to its diverse cellular functions and could reveal new opportunities for intervention in pathological contexts .

What standardized experimental designs would best address contradictions in the literature regarding NEK9 T210 phosphorylation function?

Standardized experimental approaches to resolve contradictions regarding NEK9 T210 phosphorylation function:

• Comprehensive phosphorylation site analysis:

  • Systematic phosphoproteomic mapping of all NEK9 phosphorylation sites

  • Quantitative temporal profiling across synchronized cell cycle stages

  • Context-dependent analysis across different cell types and conditions

  • Creation of a comprehensive phosphorylation site mutation panel

• Unified functional readouts:

  • Standardized cell cycle analysis protocols

  • Consistent mitotic phenotype scoring criteria

  • Uniform kinase activity assay conditions

  • Agreed-upon panel of substrate phosphorylation events to monitor

• Cross-laboratory validation approaches:

  • Development of common reagents and cell lines

  • Establishing multi-site experimental protocols

  • Centralized database for raw data sharing

  • Meta-analysis of published and unpublished findings